Navigation Links
Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
Date:7/22/2008

t guides the surgeon's moves during the laser treatment and a sterile sheath for working in the operating room. EkkyLite(TM) activates and stimulates the skin regeneration process resulting in faster healing, while preventing, reducing and sometimes completely erasing surgical scars.

The therapeutic, aesthetic and practical benefits provided by EkkyLite(TM) makes it the first laser technology accessible to all surgeons: not only plastic surgeons but also specialists experiencing scarring issues such as dermatologists, obstetricians, trauma specialists...

Currently in clinical phase, the commercialization of the Ekkylite(TM) system is forecasted for 2008 in France and for 2009 successively in Europe and the United States. Based in Meyreuil, France, Ekkyo has 8 staff members as of December 2007.

More on http://www.ekkyo.com

*Alexandre C. Capon et al. LSM-08-0066 (20657)

Lasers in Surgery and Medicine publishes the highest quality research and clinical manuscripts in areas relating to the use of lasers in medicine and biology. The journal publishes basic and clinical studies on the therapeutic and diagnostic use of lasers in all the surgical and medical specialties.


'/>"/>
SOURCE EKKYO
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
4. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
5. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
6. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... of the ResMed Data Exchange program, a comprehensive ... medical equipment (HME) and other health care providers. ... secure access to critical patient information. It integrates ... AirView™ and U-Sleep™ patient management platforms with customers, ...
(Date:10/20/2014)... PRINCETON, N.J. , Oct. 20, 2014 /PRNewswire/ ... Taiho Pharmaceutical Co., Ltd. ( Japan ... Administration (FDA) granted Fast Track designation for TAS-102 ... combination anticancer drug under investigation for the treatment ... the Company has initiated a rolling NDA submission ...
(Date:10/20/2014)... October 20, 2014 Norgine B.V. ... novel, low volume bowel preparation, NER1006, presented at the ... College of Gastroenterology (ACG), Philadelphia, PA ... stool weight and co-primary endpoint of cleansing success. The ... vs. MOVIPREP ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will ... Tuesday, February 15, 2011.  The presentation is scheduled for ... through the Company,s web site, www.regeneron.com , on ... presentation will be available after the live webcast through ...
... Feb. 8, 2011 IPC The Hospitalist Company, Inc. (Nasdaq: ... practice company, announced today that it will report results for ... Monday, March 7, 2011, after the market close. ... 5:00 p.m. ET (2:00 p.m. PT) on March 7, 2011 ...
Cached Medicine Technology:IPC The Hospitalist Company, Inc. to Report Fourth Quarter 2010 Results 2
(Date:10/20/2014)... 2014 The Advocator Group, LLC ... the American Foundation for Suicide Prevention’s (AFSP) Out of ... a not-for-profit organization that hosts hundreds of community walks ... events are used to help understand and prevent suicide ... relationships as well. , The Advocator Group shares ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, ... estimates member hospital ROI on membership dues at 12.5. In ... provides $12.50 in value to member hospitals. The calculation used ... Dues)/Member Dues. , “This is the first time we’ve ... think the methodology is really sound,” said Bill Ryan ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... and growth hormone expert from University Hospitals Rainbow Babies and ... New England Journal of Medicine commenting on a ... doses of estrogen, as well as growth hormone, years before ... benefits. With her co-author Dr. Robert L. Rosenfield, ...
... need to proactively engage lesbian, gay, bisexual, and transgender ... populations to identify and better understand health conditions that ... of Medicine. The scarcity of research yields an ... is further fragmented by the tendency to treat sexual ...
... life-threatening bloodstream infections in children with peripherally inserted central ... removing the device as early as possible, according to ... March 31 in the journal Clinical Infectious Diseases ... Saturday, April 2, at the annual meeting of the ...
... News) -- In an update to its ongoing radiation ... U.S. government officials announced late Wednesday that milk sampled ... radiation not likely to cause harm to humans. ... and Drug Administration and the Environmental Protection Agency, the ...
... field continues to grow. Following the successful First ... the Second International Conference on Immune Tolerance will ... research and insights into the mechanisms and treatment ... diseases, inflammation and cancer. This Conference is supported ...
... to a riddle or understand the solution to a problem, ... our head. But what happens after the ,Aha!, moment? Why ... stick in our memory? ,Much of memory research involves ... the group of Prof. Yadin Dudai of the Institute,s Neurobiology ...
Cached Medicine News:Health News:Assessing the value of treatments to increase height 2Health News:Researchers need to engage lesbian, gay, bisexual, and transginder populations in health studies 2Health News:Remove children's catheters as soon as possible to prevent bloodstream infections 2Health News:2nd International Conference on Immune Tolerance 2Health News:Getting a grasp on memory 2
... Farnsworth panel D15 test evaluation has ... to arrange caps with automatic creation ... manual color deficiency analysis, calculation of ... age-corrected CCI, eye selection (OD, OS, ...
... test is used to separate ... vs normal. Farnsworth D15 come ... the patient to select the ... box is closed and the ...
HRR/Amsler book combo with occluding glasses....
Ishihara test chart book for color blindness. 14 plate. A simple accurate method for discovering congenital color blindness....
Medicine Products: